These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7669597)

  • 1. Quality of pharmacokinetic research in oncology.
    Siderov J; Brien JE; Morgan DJ; Zalcberg J; Cosolo W
    Br J Cancer; 1995 Sep; 72(3):792-4. PubMed ID: 7669597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetically guided administration of chemotherapeutic agents.
    van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.
    Comets E; Zohar S
    Clin Pharmacokinet; 2009; 48(6):387-95. PubMed ID: 19650677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
    Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
    Ornstein MC; Rini BI
    Clin Cancer Res; 2016 Dec; 22(23):5626-5628. PubMed ID: 27663599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
    Maillet D; Gan HK; Blay JY; You B; Péron J
    Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and population pharmacokinetics in pediatric oncology.
    Sassen SDT; Zwaan CM; van der Sluis IM; Mathôt RAA
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28132. PubMed ID: 31876123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and early clinical studies of selected new drugs.
    Kaye SB; Workman P; Graham MA; Cassidy J; Jodrell D
    Cancer Surv; 1993; 17():371-96. PubMed ID: 8137348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioanalytical aspects of clinical mass balance studies in oncology.
    Dubbelman AC; Rosing H; Schellens JH; Beijnen JH
    Bioanalysis; 2011 Dec; 3(23):2637-55. PubMed ID: 22136052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.
    Tomita M; Aoki Y; Tanaka K
    Clin Pharmacokinet; 2004; 43(8):515-27. PubMed ID: 15170366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population and Bayesian pharmacokinetics in oncology.
    Ranson MR; Scarffe JH
    Clin Oncol (R Coll Radiol); 1994; 6(4):254-60. PubMed ID: 7986764
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.